Quintiles pools postmarketing services into a single offering

Quintiles ($Q) has unveiled a new offering that combines its pharmacovigilance, label management, risk-benefit research and analytics into a single product, touting the service as a catch-all for approved drugs. The new platform, called Marketed Product Maintenance, is designed to provide all the data-driven information clients need to get the most out of their products, Quintiles said, handling postapproval requirements to boost return on investment. More

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.